CSIMarket
 
Fate Therapeutics Inc   (FATE)
Other Ticker:  
 
 
Price: $5.1800 $-0.39 -7.002%
Day's High: $5.72 Week Perf: 20.19 %
Day's Low: $ 5.16 30 Day Perf: 34.9 %
Volume (M): 2,902 52 Wk High: $ 8.83
Volume (M$): $ 15,034 52 Wk Avg: $3.97
Open: $5.44 52 Wk Low: $1.63



 Market Capitalization (Millions $) 511
 Shares Outstanding (Millions) 99
 Employees 208
 Revenues (TTM) (Millions $) 106
 Net Income (TTM) (Millions $) -173
 Cash Flow (TTM) (Millions $) -49
 Capital Exp. (TTM) (Millions $) 13

Fate Therapeutics Inc
Fate Therapeutics Inc is a biopharmaceutical company that develops advanced cellular therapies that can replace or repair damaged cells in people suffering from severe diseases.
The company is based in San Diego, California, and was founded in 2007.
The company's innovative approach to therapy involves taking cells from a patient's body, engineering them to become specific types of cells, and then reintroducing them into the patient's body, where they can replace or repair damaged cells.
This approach offers a potential solution to many severe diseases, including cancer, genetic disorders, and autoimmune diseases.
Fate Therapeutics Inc's main product is FT516, a treatment designed to replace natural killer cells that work to identify and destroy cancer cells in the body with healthy cells produced outside the body.
They also have other products in development, including FT500, a cancer-killing cell therapy, and FT819, a CAR T-cell therapy for B-cell malignancies.
The company has a strong focus on research and development, and they have partnerships with many leading medical and academic institutions worldwide.
They have also established a strong intellectual property portfolio, which includes over 300 patents and patent applications in the field of cellular therapy.
In summary, Fate Therapeutics Inc is a cutting-edge biopharmaceutical company that develops advanced cellular therapies that can provide a potential cure for many severe diseases.
They have a strong focus on research, development, and intellectual property, making them a leader in the field of cellular therapy.


   Company Address: 12278 Scripps Summit Drive San Diego 92131 CA
   Company Phone Number: 875-1800   Stock Exchange / Ticker: NASDAQ FATE
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Stock Market Announcement

Fate Therapeutics Grants Restricted Stock Units to Newly-Hired Employees, Enhancing Long-Term Incentives

Published Tue, Jul 2 2024 8:01 PM UTC



In a notable move towards attracting and retaining talent, Fate Therapeutics, a leading clinical-stage biopharmaceutical company, recently announced the grant of restricted stock units (RSUs) to three newly-hired non-executive employees. The grants, totaling 28,200 shares of the company's common stock, were approved by the Compensation Committee of the Board of Dir...

Clinical Study

Fate Therapeutics Pioneers Off-the-Shelf CAR T-Cell Therapies, Showing Promise in Treating Lupus and HER2-expressing Advanced Solid Tumors

Published Thu, May 9 2024 12:30 PM UTC

Fate Therapeutics, a leading biopharmaceutical company focused on the development of off-the-shelf cell therapies, recently announced significant advancements in their groundbreaking CAR T-cell programs for the treatment of autoimmune disorders and advanced solid tumors. The company has successfully treated the first Lupus patient in their Phase 1 Autoimmunity Study using th...

Clinical Study

Revolutionizing Autoimmune Disease Management: The Promising Potential of FT522 CAR NK Cell Product Candidate

Published Fri, May 3 2024 8:30 PM UTC

In a presentation at the recent American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, Fate Therapeutics Inc. unveiled compelling preclinical data related to their novel drug candidate, FT522. This investigational compound demonstrates promising potential in addressing autoimmune diseases by triggering rapid and deep depletion of SLE donor CD19+ B cells.Ground-break...

Shares

Fate Therapeutics Implements Inducement Award Program to Attract Top Talent and Secures Funding for Innovative Cellular Immunotherapies

Published Tue, Apr 2 2024 8:01 PM UTC

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, a clinical-stage biopharmaceutical company specializing in induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for cancer and autoimmune disorders, recently announced the granting of restricted stock units (RSUs) to a newly-hired non-executiv...

Financing Agreement

Fate Therapeutics Raises $100 Million to Elevate Patient Care with iPSC-derived Cellular Immunotherapies.

Published Tue, Mar 19 2024 12:45 PM UTC

Fate Therapeutics Raises $100 Million in Underwritten Offering and Concurrent Private Placement
SAN DIEGO, March 19, 2024 - Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on developing induced pluripotent stem cell (iPSC)-derived cellular immunotherapies, has successfully priced its underwritten offering of 14,545,454 shares o...






 

Fate Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com